The following is information SHPA has received from medicines manufacturers such as alerts regarding supply problems, discontinued items etc which may be useful to SHPA members.
Other resources:
- TGA Medicine Shortages Information Initiative which provides up-to-date information about temporary or permanent disruption (discontinuation) to the supply of a medicine in Australia. You can also subscribe to updates so you will receive an email when there is a new or updated medicine shortage reported by sponsors to the TGA and published on the Medicine Shortages Information website.
- TGA Australian Recall Actions for recalls of medicines, medical devices and biologicals.
- TGA Alerts which advises consumers, health professionals and industry about new safety information regarding therapeutic product
Notice of withdrawal of Sartorius 5µm Filters present in cartons of AmBisome®, amphotericin B, 50mg, powder for injection, AUST R 53783
11 February
Gilead has been notified of a quality defect issue by our supplier, Sartorius, in relation to specific lots f 5µm sterile filters, which are co-packed in cartons of the AmBisome product. The filter is called
Minisart® Filter 17594-GJ. Sartorius has informed Gilead that the filter lots packaged with the AmBisome batches listed in the Appendix may be releasing fibres and particles, which may pose a risk
to the patient.
Shortage of Nardil phenelzine 15mg (as sulfate) tablet bottle (AUST R 93600) and alternative supply arrangement under Section 19A of the Therapeutic Goods Act 1989
10 February
As you may be aware, the Australian registered medicine, Nardil phenelzine 15mg (as sulfate) tablet bottle (AUST R 93600), sponsored by Link Medical Products Pty Ltd, has been discontinued from the Australian market. To address this medicine shortage, Generic Health Pty Ltd has been able to arrange supply of an alternative product, Phenelzine Sulfate USP 15 mg Tablets (Lupin Pharmaceuticals) (PBS-listed), on a temporary basis.
Shortage of ONCOTICE BCG 5 hundred million CFU powder for injection vial (AUST R 59912)
9 February
LINK advises that due to the shortage of the Australian registered ONCOTICE BCG 5 hundred million CFU powder for injection vial (AUST R 59912), LINK has arranged the supply of an alternative product. LINK can supply BCG Culture SSI BCG 30 mg/vial (AJ Vaccines). BCG Culture SSI BCG 30 mg/vial (AJ Vaccines) is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 31 January 2022.
Shortage of DBL ERGOMETRINE INJECTION, ergometrine maleate (500 mcg/mL) ampoule
9 February
LINK has advised that due to a shortage of the Australian registered DBL ERGOMETRINE INJECTION, ergometrine maleate (500 mcg/mL) ampoule (AUST R 58866), LINK has arranged the supply of an alternative product. LINK can supply ERGONOVINE MALEATE INJECTION (ergonovine maleate injection, USP) 0.25 mg/mL, ampoules registered and marketed in Canada.
Phenelzine Sulfate USP 15 mg Tablets (Lupin Pharmaceuticals) – supply arrangement
9 February
On 9 February, Generic Health Pty Ltd advised that the above overseas-registered product has been approved for temporary supply under the Section 19A of the Therapeutic Goods Act 1989. In response to the discontinuation of the Australian registered medicine, NARDIL phenelzine 15mg (as sulfate) tablet bottle (AUST R 93600), Generic Health Pty Ltd has been able to arrange supply of an alternative product, Phenelzine Sulfate USP 15 mg Tablets (Lupin Pharmaceuticals). See additional information here.
Shortage of the Australian registered IMOGAM RABIES PASTEURIZED human rabies immunoglobulin 150 IU/mL injection vial (AUST R 72931)
2 February
LINK advises that due to the shortage of the Australian registered IMOGAM RABIES PASTEURIZED human rabies immunoglobulin 150 IU/mL injection vial (AUST R 72931), LINK has arranged the supply of an alternative product. LINK can supply KamRAB 150 IU/mL Solution for injection - 2 mL vial (Human Rabies immunoglobulin), registered and marketed in Israel. KamRAB 150 IU/mL Solution for injection - 2 mL vial (Human Rabies immunoglobulin) is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 31 January 2022.
Shortage of Adrenaline 1:1,000 (1 mg/1 mL) ampoules and alternative supply
1 February
LINK advises that due to the shortage of Australian registered ADRENALINE-LINK 1:1,000 1mg/mL adrenaline (epinephrine) acid tartrate injection BP ampoule (AUST R 12048), LINK has arranged the supply of an alternative product, ADRENALINE RENAUDIN, adrenaline 1 mg/mL solution for injection 1 mL ampoule, registered and marketed in France. ADRENALINE RENAUDIN 1 mg/mL ampoules are NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 30 April 2021.
Shortage of MINIRIN desmopressin acetate 10 microgram/actuation nasal spray and alternate supply arrangement
29 January 2021
The Australian registered medicine, MINIRIN desmopressin acetate 10 microgram/actuation nasal spray (AUST R 59320) sponsored by Ferring Pharmaceuticals Pty Ltd is unavailable due to product recall. Medsurge has been able to arrange for the supply of Desmopressin Acetate Nasal Spray 10mcg/0.1mL (Apotex) as an alternative product on a temporary basis. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31 January 2022.
Shortage of NEO-MERCAZOLE carbimazole 5mg tablet bottle ARTG 194296 and alternate supply arrangement
29 January 2021
Medsurge advises the Australian registered medicine NEO-MERCAZOLE carbimazole 5 mg tablet bottle ARTG 194296 sponsored by Amdipharm Mercury Australia Pty Ltd is unavailable due to manufacturing delays. Supply of NEO-MERCAZOLE carbimazole 5 mg tablet bottle ARTG 194296 is expected to resume 28 February 2021. Medsurge has been able to arrange for supply of Carbimazole 5 mg tablets (Morningside Health) as an alternative product on a temporary basis. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31 March 2021.
Shortage of DIASP SR Dipyridamole/Aspirin 200 mg/25 mg modified release capsules bottle and ASASANTIN SR dipyridamole 200mg/aspirin 25mg sustained release capsule bottle
29 January 2021
Medsurge advises the Australian registered medicine ASASANTIN SR dipyridamole 200mg/aspirin 25mg sustained release capsule bottle AUST R 68051 sponsored by Boehringer Ingelheim Pty Ltd has been discontinued. The Australian registered medicine DIASP SR Dipyridamole/Aspirin 200 mg/25 mg modified release capsules bottle AUST R 210808 sponsored by Arrow Pharma Pty Ltd is unavailable due to unexpected increase in demand. Medsurge has been able to arrange for the supply of Aspirin and Extended-release Dipyridamole Capsules 25mg/200mg (USA) as an alternative product on a temporary basis. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31 August 2021.
Shortage of CYKLOKAPRON tranexamic acid 500mg tablet bottle and alternate supply arrangement
29 January 2021
Medsurge advises the Australian registered medicine, CYKLOKAPRON tranexamic acid 500mg tablet bottle (AUST R 14463), sponsored by Pfizer Australia Pty Ltd is in short supply due to unexpected increase in demand. Medsurge has been able to arrange for supply of an alternative product, Tranexamic acid 500mg tablets (TILLOMED) 60 tablets, on a temporary basis. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31 May 2021.
Shortage of DBL Ergometrine Injection
29 January
The Department of Health advises that an upcoming shortage of DBL Ergometrine Injection (AUST R 58866) from 12 February 2021 until 18 June 2021. Ergometrine is used in the hospital setting during obstetric procedures following the delivery of the placenta to promote involution of the uterus in order to treat haemorrhage. The alternative product, Ergonovine maleate injection USP (0.25 mg/mL) ampoule, is usually only supplied overseas but has been approved under section 19A of the Therapeutic Goods Act 1989 for use during the shortage of DBL Ergometrine Injection (ergometrine maleate injection ampoule), AUST R58866.
Supply Interruption Notice for DBL ERGOMETRINE INJECTION 500MCG/1ML ampoule [AUST R 58866]
20 January 2021
Pfizer advises of an upcoming interruption to supply of DBL ERGOMETRINE INJECTION 500MCG/1ML ampoule [AUST R 58866] due to a shortage in active pharmaceutical ingredients for DBL Ergometrine maleate injection ampoule. Pfizer is the sole supplier of this product in Australia. There are no safety concerns with the above product. Alternate suppliers, including LINK Healthcare may have potential therapeutic alternatives.
Medsurge S19A approval – Sertraline 50 mg and 100 mg tablets (S19A) (pack of 30)
12 January
Medsurge advises that Sertraline 50 mg and 100 mg tablets, USP (Cipla) are now available as S19A until 30 June 2021, due to the shortage of APO-SERTRALINE sertraline (as hydrochloride) 50 mg tablet blister pack (ARTG 213177) and APO-SERTRALINE sertraline (as hydrochloride) 100 mg tablet blister pack (ARTG 213180).
Tenofovir Disoproxil Emtricitabine Mylan 300/200 tablets
8 January
Link Medical Products Pty Ltd (LINK) advises that due to a shortage of Australian registered Tenofovir Disoproxil Emtricitabine Mylan 300/200 tablets (AUST R 265834) (which contains 300 mg of tenofovir disoproxil as maleate (equivalent to 245 mg of tenofovir disoproxil and 200 mg of emtricitabine)1, LINK has arranged supply of an alternative product, Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd) (which contains 245 mg of tenofovir disoproxil and 200 mg of emtricitabine) on a temporary basis. Please note: Tenofovir Disoproxil Emtricitabine Mylan 300/200 tablets (AUST R 265834) contains Tenofovir disoproxil as maleate salt, whereas Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd) contains tenofovir disoproxil as phosphate salt. Both products contain 245 mg Tenofovir disoproxil. Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd) are not registered in Australia and supply is granted under an approval granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 28 February 2021. Queries should be directed to medicine.shortages@linkhealthcare.com.au.
Neo‐Mercazole carbimazole 5mg tablet bottle
7 January
Neo‐Mercazole carbimazole 5mg tablet bottle (ARTG 194296), sponsored by Amdipharm Mercury Australia Pty Ltd is in short supply due to manufacturing delays. Supply of Neo‐Mercazole carbimazole 5 mg tablet bottle is expected to resume 28 February 2021. Seed Pharma Pty Ltd has been able to arrange supply of an alternative product Carbimazole 5 mg tablets (DAWA Ltd) on a temporary basis. This product is NOT registered in Australia and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act until 31 March 2021 for the following indication(s): Therapy of hyperthyroidism. Definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. Preparation for thyroidectomy. Before and after radioactive iodine treatment. Carbimazole 5 mg tablets (DAWA Ltd) is registered and marketed in the UK. Queries and orders should be directed to anz@seedpharma.com.
Recall action: ZERBAXA ceftolozane sulfate/tazobactam sodium 1000 mg/500 mg powder for injection
23 December 2020
MSD, following consultation with the Therapeutic Goods Administration (TGA), is conducting a recall in Australia of ZERBAXA, batches S036990 and T025455. Due to a recent manufacturing issue identified during the routine testing of ZERBAXA (ceftolozane/tazobactam), manufacturing of the product has been temporarily stopped. The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. The investigation into the source of the R. Pickettii is ongoing and the seven batches have not been released to the market.
Shortage of Famotidine 20 mg and 40 mg tablets and alternative supply arrangement
18 December 2020
Due to a shortage and discontinuation of multiple Australian registered Famotidine 20 mg and 40 mg tablets, LINK has arranged the temporary supply of alternative products. LINK can supply Famotidine 20 mg tablets (Tillomed) and Famotidine 40 mg tablets (Tillomed), registered and marketed in the United Kingdom. Famotidine 20 mg and 40 mg tablets (Tillomed) are not registered in Australia and supply is granted under an exemption by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 30 April 2022. Queries should be directed to medicine.shortages@linkhealthcare.com.au.
Shortage of DBL Pethidine Hydrochloride 50 mg/1 mL & 100 mg/2 mL injection BP ampoules and alternative supply arrangement
11 December 2020
Due to a shortage of the Australian registered DBL Pethidine Hydrochloride 50 mg/1 mL and 100 mg/2 mL injection BP ampoule (AUST R 107386 and AUST R 107387), LINK has arranged the supply of an alternative product. LINK can supply Pethidine 50 mg/mL Solution for Injection ampoules (50 mg/mL & 100 mg/2 mL) registered and marketed in the United Kingdom. Pethidine 50 mg/mL solution for injection ampoules (50 mg/mL and 100 mg/2 mL) are NOT registered in Australia and supply is granted under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act until 31 October 2021. Queries should be directed to medicine.shortages@linkhealthcare.com.au.
Shortage of famotidine 20 mg and 40 mg tablets and alternative supply arrangement
30 November 2020
LINK has advised, that due to a shortage and discontinuation of multiple Australian-registered famotidine 20 mg and 40 mg tablets, they have arranged the temporary supply of alternative products. LINK can supply Famotidine 20 mg tablets (Tillomed) and Famotidine 40 mg tablets (Tillomed), registered and marketed in the United Kingdom. Famotidine 20 mg and 40 mg tablets (Tillomed) are not registered in Australia and supply is granted under an exemption by the Therapeutic Goods Administration under Section 19A of the Therapeutic Goods Act, 1989 until 31 January 2021.
Shortage of UREX FOTRE furosemide (Frusemide) 500mg tablet blister pack AUST R 196972
25 November 2020
Medsurge has advised that Furosemid-Ratiopharm 500mg Furosemide Tablets is now available as S19A until 15 February 2021 due to the shortage of UREX FOTRE furosemide (Frusemide) 500 mg tablet blister pack AUST R 196972. Further information →
Shortage of fluoxetine 20 mg (as hydrochloride) capsule blister pack and alternate supply arrangement
9 November 2020
Australian registered fluoxetine products, LOVAN fluoxetine 20 mg (as hydrochloride) capsule blister pack AUST R 54700 sponsored by Alphapharm Pty Ltd and PROZAC 20 fluoxetine 20 mg (as hydrochloride) capsule blister pack (ARTG 14653) sponsored by Eli Lilly Australia Pty Ltd are in shortage. Medsurge has been able to arrange for supply of Fluoxetine capsules USP 20 mg (ScieGen) 100 capsule bottle as an alternative product on a temporary basis.
MS Contin® (modified-release morphine sulphate) suspension range discontinued
October 2020
Mundipharma has advised that due to the scarcity of specific components, and no viable alternatives for continuing manufacture, production of the MS Contin® (modified-release morphine sulphate) suspension range (20mg, 30mg, 60mg, 100mg, 200mg) has ceased. Advice regarding alternative strong opioid analgesic medicines which may be suitable based on the prescriber’s clinical management is included in the notice.
Shortage of DBL Gentamicin 10 mg/1 mL (as sulfate) injection BP ampoule and alternative supply arrangement
22 October 2020
LINK advises that due to a shortage of Australian registered DBL Gentamicin 10mg/1mL (as sulfate) injection BP ampoule (AUST R 16339), LINK has arranged the supply of an alternative product. LINK can supply Refobacin (gentamicin) 10 mg (10 mg/2 mL) ampoules, registered and marketed in Germany. Refobacin (gentamicin) 10mg (10mg/2mL) ampoules, is not registered in Australia and supply is granted under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 31 March 2021.
Shortage of DIASP SR Dipyridamole/Aspirin 200 mg/25 mg modified release capsules bottle and ASASANTIN SR dipyridamole 200mg/aspirin 25mg sustained release capsule bottle and alternate supply arrangement under Section 19A of the Therapeutic Goods Act
19 October 2020
Medsurge has advised that Aspirin and ER Dipyridamole 25mg/200mg capsules (Pack of 60) is now available as S19A until 31 January 2021, due to the shortage of DIASP SR Dipyridamole/Aspirin 200mg/25mg modified release capsules bottle AUST R 210808. View prescribing information →
Shortage of Epirubicin Accord 200 mg/100 mL Aust R 227997 and alternative supply arrangement
26 August 2020
Accord Healthcare Australia has advised of a shortage of Epirubicin Accord 200 mg/100 mL Aust R 227997 and alternative supply arrangement under Section 19A of the Therapeutic Goods Act 1989. The Australian registered medicine, Epirubicin Accord 200 mg/100 mL AUST R 227997, sponsored by Accord Healthcare Pty Ltd, is unavailable due to API supply issues. Supply of Epirubicin Accord 200 mg/100 mL is expected to resume March 2021. Accord Healthcare Pty Ltd has been able to arrange supply of an alternative product Epirubicin Accord 200 mg/100 mL (from Austria) on a temporary basis.
Interruption to supply for DIFLUCAN Fluconazole 50mg/5mL powder for oral suspension bottle
31 July 2020
The supply interruption is due to manufacturing delay. There are no safety concerns with the above product. Pfizer is the sole supplier of this product in Australia. Alternate suppliers, including LINK Healthcare, may have potential therapeutic alternatives. LINK Healthcare can be contacted on telephone 1800 181 060 or email customerservice@linkhealthcare.com.au. Complete information regarding the approved indications for DIFLUCAN FLUCONAZOLE POWDER FOR ORAL SUSPENSION can be located in the Product Information available at www.tga.gov.au.
Shortage of TOFRANIL 25 imipramine hydrochloride 25mg tablet blister pack
10 July 2020
The Australian registered medicine, TOFRANIL 25 imipramine hydrochloride 25mg tablet blister pack (AUST R: 60673), sponsored by Amdipharm Mercury Australia Pty Ltd, is currently in shortage due to manufacturing issues. Pro Pharmaceuticals Group has arranged for the supply of an alternative product, IMIPRAMINE HYDROCHLORIDE TABLETS USP, 25 MG 100 TABLETS (LEADING PHARMA LLC). This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31st December 2020 for the following indications: major depression; nocturnal enuresis.
Shortage of auranofin (Ridaura®) Aust R 13000
29 June 2020
The Australian registered medicine, auranofin (Ridaura®) Aust R 13000, sponsored by Amdipharm Mercury (Australia) Pty Ltd, has been discontinued. ADVANZ PHARMA has been able to arrange supply of an alternative product, Ridaura (Canada), on a temporary basis. ADVANZ PHARMA has been able to arrange supply of an alternative product, Ridaura (Canada), on a temporary basis. This product is NOT registered in Australia and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 30 June 2021 for the following indication(s): “Adjunctive treatment of active classical or definite rheumatoid arthritis in adults who have an insufficient therapeutic response to, or are intolerant of, an adequate trial of a baseline therapeutic program, including among other measures, full doses of one or more nonsteroidal anti‐inflammatory drugs. Ridaura is not indicated in non‐rheumatoid arthropathies such as osteoarthrosis. Ridaura should be added to a comprehensive baseline therapeutic program.”
Discontinuation of Nardil (Phenelzine Sulfate)
22 June 2020
Joint statement from the Therapeutic Goods Administration, the Royal Australian and New Zealand College of Psychiatrists, and the Society of Hospital Pharmacists of Australia: The sponsor of Nardil (phenelzine sulfate) tablets has notified the Therapeutic Goods Administration (TGA) that they can no longer supply this medication in Australia due to global issues with the manufacture of the active pharmaceutical ingredient. There are no alternative brands of phenelzine on the Australian market. Supplies of phenelzine tablets are very limited.
Interruption to supply of DBL™ Methotrexate 5mg/2mL vial
22 June 2020
Pfizer has advised of an ongoing supply interruption of DBL™ Methotrexate 5mg/2mL vials due to a manufacturing delay. There are no safety concerns with the above product. Pfizer is the sole supplier of this presentation of methotrexate in Australia. Alternate suppliers, including LINK Healthcare and Medsurge, may have potential therapeutic alternatives.
Interruption to supply for DBL™ ERGOMETRINE INJECTION 500MCG/1ML AMPS
22 May 2020
Pfizer has advised of an ongoing interruption to the supply of DBL™ ERGOMETRINE MALEATE INJECTION 500mcg/1mL amps ARTG: 58866 – pack size: 1 x 5mL vials, item code, back in stock date: late June 2020. M8008BAU. The supply interruption is due to a temperature deviation during transit. There are no safety concerns with the product. Alternate suppliers, including MEDSURGE, may have potential therapeutic alternatives. Complete information regarding the approved indications for DBL™ ERGOMETRINE MALEATE INJECTION can be located in the Product Information available on the TGA website.
Shortage of metformin modified-release 500 mg (multiple brands)
13 May 2020
The Therapeutic Goods Administration (TGA) has been notified of current shortages for multiple brands of metformin modified-release 500 mg tablets (also known as extended-release or XR tablets). The shortages are expected to continue until 5 June 2020 at the earliest. Metformin is a prescription drug used to treat type 2 diabetes. In order to reduce the impact of this shortage on patients the TGA is issuing a Serious Shortage Medicine Substitution Notice for metformin modified-release 500mg.
Discontinuation notice for DBL™ Heparin Sodium Injection BP (Sodium) 35,000 IU/35 ML vials [AUST R 16345]
29 April 2020
After a thorough review, a decision has been made by Pfizer Australia to discontinue DBL™ Heparin Sodium Injection BP (Sodium) 35,000 IU/35 mL vials from the Australian market. The effective discontinuation date is 1st May 2020 and the product will be removed from PBS listing 1 July.
Discontinuation notice for Zavedos® (Idarubicin Hydrochloride) 5 MG capsules
29 April 2020
After a thorough review, a decision has been made by Pfizer Australia to discontinue ZAVEDOS® (IDARUBICIN HYDROCHLORIDE) 5 MG CAPSULES from the Australian market. The effective discontinuation date is 1st May 2020 and the product will be removed from PBS listing 1 July.
Supply Interruption notice for DBL™ Gentamicin 10mg/1mL (as Sulfate) injection ampoule
29 April 2020
Please be advised of an ongoing interruption to the supply of the following presentation listed below:
| Presentation | Pack size | Pfizer item code | Estimated out of stock date | Back in stock date |
| DBL™ Gentamicin Injection 10mg/1mL AUST R 16339 | 5 x 1 mL ampoules | M8380BAU1 | Now | Late Aug 2020 |
Shortage of Tazocin EF 4g/500mg powder for injection vial, AUST R 132525
17 April 2020
Pfizer has advised the Australian registered medicine, TAZOCIN EF 4g/500mg powder for injection vial, AUST R 132525 sponsored by Pfizer Australia Pty Ltd is unavailable due to an unexpected manufacturing issue. Supply of TAZOCIN EF 4g/500mg powder for injection vial, AUST R 132525 is expected to resume in Jan 2021. Pfizer has been able to arrange supply of an alternative product, TAZOCIN EF 4g/500mg powder for injection vial [New Zealand] on a temporary basis.
Aminophylline injection supply interruption
6 April 2020
Pfizer has advised of an ongoing interruption to the supply of DBL™ Aminophylline injection 250 mg in 10 mL due to a capacity issues at the manufacturing site and over demand of the product. Pfizer recognises this is a critical medicine and we are working with other suppliers to source an alternative product in place of the Australian registered product during this out of stock period and an update will be provided in May.
NARDIL phenelzine 15mg tablets discontinued
6 April 2020
Link Medical Products has advised the manufacturing site for NARDIL phenelzine 15mg tablets has closed and they have been unable to secure adquate alternative options to cover the anticipated phenelzine requirements throughout 2020.
Supply status of Celltrion Healthcare Biosimilar products in Australia
11 March 2020
Celltrion Healthcare - Australia has provided an update of the supply status of Celltrion Healthcare Biosimilar products in Australia.
Neural connector changeover
30 August 2019
The Australian and New Zealand College of Anaesthetists advises neural device connectors are changing to the ISO 80369-6 standard as part of an international patient safety measure to prevent the potentially fatal administration of medicines and substances.
Long-term interruption of DBL Morphine Tartrate 120mg/1.5mL injection ampoule
26 August 2019
Pfizer has advised the supply interruption is due to an inability to source an alternate supplier for DBL MORPHINE TARTRATE 120mg/1.5mL INJECTION AMPOULE [AUST R 16324]. There are no safety concerns with the above product. Pfizer is the sole supplier of this product in Australia.
Shortage of Heparin Sodium 5000 IU/0.2 mL ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act
16 August 2019
Due to a shortage of the Australian registered DBL HEPARIN SODIUM 5000 IU/1 mL (porcine mucous) injection BP ampoule (AUST R 12881), LINK has arranged the supply of an alternative product. LINK can supply Heparin sodium 5000 IU/mL solution for injection or concentrate for solution for infusion (UK). This product is also from porcine intestinal mucosa origin. Heparin sodium 5000 IU/mL solution for injection or concentrate for solution for infusion (UK) is NOT registered in Australia and supply is granted under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 10 October 2019.
Quarantine of Endone oxycodone hydrochloride 5mg tablet blister pack (batch CW612 only)
30 July 2019
Aspen and the TGA are requesting hospital and retail pharmacies immediately quarantine all units of ENDONE oxycodone hydrochloride 5mg tablet blister pack from batch number CW612 only, until further notice, due to the potential for a rogue blister of Anamorph 30mg tablets. No stock is to be returned at this time.
Medsurge updates
17 July 2019
Medsurge have provided updates on the following medicines: AciVision 30mg/g, SINEMET CR 200mg/50mg slow release, DICLOXACILLIN, Azithromycin, Sulfamethoxazole and Trimethoprim, SINEMET tablet bottle, Fentanyl 100 microgram, STAPHYLEX and APO-FLUCLOXACILLIN and FERRO-LIQUID.
Marcain and Xylocaine Product Updates
31 May 2019
Aspen Pharmacists has updated on the shortage of Marcain and Xylocain.
Shortage of Nardil
28 May 2019
There is currently a shortage of Nardil 15mg tablets, Link medical products has arranged the supply of an alternate product
Shortage of Metoclopramide
28 May 2019
There is currently a shortage of Metoclopramide Hydrochloride Monohidrate 10mg/2L injection ampuoles. Link medical products has arranged the supply of an alternate product.
Shortage of SEPTRIN sugar-free oral liquid bottle
28 May 2019
There is currently a shortage of SEPTRIN sugar-free oral liquid, trimethoprim 40 mg/5 mL and sulfamethoxazole 200 mg/5 mL, 100 mL bottle (AUST R 11000). Link medical products has arranged the supply of an alternate product.
Shortage of HEPARIN SODIUM 5000 IU/0.2 mL
24 May 2019
There is currently a shortage of Heparin Sodium 5000. Link medical products has arranged the supply of an alternate product.
Shortage of Bleomycin sulphate powder for injection
6 May 2019
Cilpa Bleomycin have advised there is currently a shortage on Bleomycin sulphate powder for injection in Australia, there is an alternate product available as advised in the attached announcement.
Shortage of Fentanyl Citrate injection ampoules
26 April 2019
There is currently a shortage of Fentanyl Citrate 100mcg/2 m: injection ampoules. LINK medical products are distributing Fentanyl Citrate Injection USP as a substitute as advised in the attached announcement.
Shortage of SPAN K Potassium Chloride 600mg
24 April 2019
There is currently a shortage of SPAN K potassium chloride 60mg Tablet bottle. LINK medical products are distributing EURO-K 600 tablets as a substitute as advised in the attached announcement.
Marcain®, Xylocaine and Naropin Shortage - updates on shortages
18 April 2019
Aspen Pharmacare advises there is a shortage of Marcain, Xylocaine and Naropin due to a fire at AstraZeneca's Swedish manufacturing site. AZ still cannot confirm the availability of other sterile theatre packed products listed in the attached announcement.
Shortage of Atrophine Sulphate pre-filled syringe
11 April 2019
There is currently a shortage of Atrophine Sulphate 1mg/5mL BP pre-filled syringe. LINK are supplying Atrophine Sulfate 1mg/5mL as a substitute as advised in the attached announcement.
Shortage of ATROPINE INJECTION BP atropine sulfate monohydrate 600 microgram
4 April 2019
There is currently a shortage of ATROPINE INJECTION BP atropine sulfate monohydrate 600 microgram/1 mL injection BP ampoule, ATROPINE INJECTION BP atropine sulfate monohydrate 1.2 mg/1 mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act. An alternate product is available.
Shortage of azithromycin 500mg IV injection vial and supply of alternative medicine
21 March 2019
There is currently a shortage of Link azithromycin 500mg IV, alternate medicine ZEDBAC, azithromycin 500mg powder for solution vials as it has been granted an extension by the Therapeutic Goods of Australia.
Marcain®, Xylocaine and Naropin Shortage - updates on shortages
18 March 2019
Notification of Morphine Sulphate Injection BP in 1mL ampoules
15 March 2019
There is currently a shortage of Link Morphine Sulphate Injection BP in 1mL ampoules until June 30, 2019. Link medical products can supply an alternate product Morphine Sulfate Injection BP 30mg in 1mL ampoules.
Shortage of DBL PETHIDINE HYDROCHLORIDE 50mg/1mL & 100mg/2mL injection BP ampoules and supply of alternative medicine
There is currently a shortage of Link medications DBL PETHIDINE HYDROCHLORIDE 50mg/1mL and 100mg/2mL injection BP ampoules, alternate medicine, Pethidine 50 mg/mL Solution for Injection ampoules has been granted an extension by the Therapeutic Goods of Australia.
Notification of some Marcain, Xylocaine and Naropin product shortage
4 March 2019
Due to a fire at AstraZeneca’s (AZ) Swedish manufacturing site, Aspen have provided an update regarding the availability of Naropin, Xylocaine and Marcain (Sterile Theatre Packed Polyamp) products, and Xylocaine with Adrenaline, Marcain with Adrenaline & other local anaesthetics.
Notification of Etopophos 100mg product shortage
6 February 2019
There is currently a stock shortage of Bristol Myers Squibb medication, Etopophos 100mg until late February. However, Etopophos 1000mg (funded on the PBS) is still available without any supply restrictions.
Notification of some Marcain, Xylocaine and Naropin product shortage
31 January 2019
Due to a fire at AstraZeneca’s (AZ) Swedish manufacturing site, Aspen have provided an update regarding the availability of Naropin, Xylocaine and Marcain (Sterile Theatre Packed Polyamp) products, and Xylocaine with Adrenaline, Marcain with Adrenaline & other local anaesthetics.
ISUPREL isoprenaline hydrochloride 200 microgram/1mL injection ampoule
14 January 2019
Orpharma advises due to the shortage of the Australian registered ISUPREL isoprenaline hydrochloride 200 microgram/1mL injection ampoule, Orpharma has arranged the supply of an alternative product. Orpharma will supply ISOPRENALINE HYDROCHLORIDE MONICO 0.2mg/1mL solution for injection ampoule, registered and marketed in Italy.
ADRENALINE RENAUDIN, adrenaline 1mg/mL solution for injection ampoule
21 December 2018
Due to the shortage of Australian registered ADRENALINE-LINK 1:1,000 1mg/mL adrenaline (epinephrine) acid tartrate injection BP ampoule (AUST R 10248) until mid-April 2019, LINK has arranged the supply of an alternative product. LINK can supply ADRENALINE RENAUDIN, adrenaline 1mg/mL solution for injection ampoule, registered and marketed in France.
Metformin Hydrochloride Slow Release 500mg and 1000mg tablets
20 December 2018
LINK has advised that due to a shortage of metformin hydrochloride 500mg and 1000mg extended release tablets, LINK has arranged the supply of an alternative product, Yaltormin SR 500mg Prolonged Release Tablets and Yaltormin SR 1000mg Prolonged Release.
Nefedipine 20mg modified release tablets
12 December 2018
Medsurge has advised that ADALAT OROS nifedipine 20mg tablet blister pack is in short supply due to manufacturing issues. Medsurge previously arranged to supply an alternative product Nifedipine AL T 20 Retard 20mg tablet blister pack, on a temporary basis however this approval has lapsed and Medsurge will cease the supply of this alternative product.
Nifedipine 10mg immediate release tablets
12 December 2018
Medsurge advises that ADALAT 10 nifedipine 10mg tablet blister pack has been discontinued and advises that medical professionals use the alternative ADEFIN 10 nifedipine 10mg tablet blister pack.
Marcain®, Xylocaine and Naropin Shortage - updates on shortages
30 November 2018
Aspen Pharmacare advises there is a shortage of Marcain, Xylocaine and Naropin due to a fire at AstraZeneca's Swedish manufacturing site. AZ still cannot confirm the availability of other sterile theatre packed products listed in the attached announcement.
Tofranil imipramine hydrochloride 25mg tablets
2 October 2018
LINK has advised that due to a shortage of TOFRANIL, imipramine hydrochloride 25 mg tablets, AUST R 60673, LINK has arranged the supply of an alternative product Imipramin-neuraxpharm 25 mg.
Moxifloxican 400mg tablet blister pack
2 October 2018
LINK has advised that due to a shortage of AVELOX moxifloxacin 400 mg (as hydrochloride) tablet blister pack (AUST R 75766) and MOXIFLOXACIN APOTEX moxifloxacin (as hydrochloride monohydrate) 400 mg film coated tablet blister pack (AUST R 223564), LINK has arranged the supply of an alternative product Moxifloxacin (Actavis) 400 mg Film-coated Tablets registered and marketed in the United Kingdom.
SPAN K potassium chloride 600mg tablet bottle
20 September 2018
LINK has advied that due to a shortage of SPAN K potassium chloride 600mg tablet bottle, LINK has arranged the supply of an alternative product EURO-K 600 potassium chloride 600mg sustained release tablets USP.
Suxamethonium Chloride Injection BP - updated temperative excursion data
19 September 2018
AstraZeneca advises that the accelerated stability data for Suxamethonium Chloride BP Polyamp DuoFit has been updated following completion of in-house stability tests for temperature excursions in August 2018.
SEPTRIN sugar-free oral liquid bottle
18 September 2018
LINK has advised that due to the shortage of SEPTRIN sugar-free oral liquid, trimethoprim 40mg/5ml and sulfamethoxazole 200mg/5ml, 100ml bottle, LINK has arranged for the supply of NOPIL fur Kinder Sirup, trimethoprim 40mg/5ml and sulfamethoxazole 200mg/5ml, 100ml bottle.
MYAMBUTOL ethambutol hydrochloride 100mg tablet bottle discontinuation
6 September 2016
Orpharma advises that due to the discontinuation of the Australian registered MYAMBUTOL ethambutol hydrochloride 100mg tablet bottle, Orpharma has arranged the supply of ETHAMBUTOL (ethambutol hydrochloride) 100 mg tablet, registered in the UK.
FENTANYL CITRATE 100 mcg/2 mL injection ampoule shortage
5 September 2018
LINK advises that due to a shortage of the Australian registered ASPEN FENTANYL fentanyl (as citrate) 100 mcg/2 mL solution for injection and 500 mcg/10 mL solution for injection, LINK has arranged for the alternative supply of Fentanyl 50 mcg/ml solution for injection (100 mcg/2 mL and 500/10 mL).
DBL ERGOMETRINE INJECTION 500 mcg/mL ampoule shortage
31 August 2018
LINK advises that due to a shortage of the Australian registered DBL ERGOMETRINE INECTION, ergometrine maleate (500 mcg/mL) ampoule, LINK has arranged the alternative supply of ERGONOVINE MALEATE INJECTION (ergonovine maleate injection, USP) 0.25 mg/mL, ampoules registered and marketing in Canada.
ISUPREL isoprenaline hydrochloride 200 micrograms/1mL injection ampoule shortage - update
27 August 2018
Orpharma advises that due to the shortage of Australian registered ISUPREL isoprenaline hydrochloride 200 microgram/1mL injection ampoule, the supply of an alternative product has been arranged. Orpharma will supply ISOPRENALINE HYDROCHLORIDE MONICO 0.2mg/1mL solution for injection ampoule, registered and marketed in Italy.
Lomustine (CEENU) 100mg cessation of supply
7 August 2018
Bristol-Myers Squibb Australia advises that the 100mg ampoules of Lomustine(CEENU) will be no longer available in Australia from November 2018. The 10mg and 40mg ampoules will continue to be available. This change has occurred due to cessation of global manufacturing of the 100mg ampoule.
HEPARIN SODIUM 5000 IU/5 mL ampoule shortage
12 July 2018
LINK advises that due to a shortage of the Australian registered DBL HEPARIN SODIUM (porcine mucous) 5000IU/5mL injection ampoule (AUST R 49232), LINK has arranged the supply of Heparin sodium 1,000 I.U./mL solution for injection or concentrate for solution for infusion, 5mL ampoules (5,000 I.U./5mL) registered and marketed in the United Kingdom.
TOFRANIL, imipramine hydrochloride 25mg tablets
1 July 2018
TOFRANIL, imipramine hydrochloride 25 mg tablets, AUST R 60673, LINK has arranged the supply of an alternative product currently registered in Germany. This product is Imipramin-neuraxpharm 25 mg and supply is authorised under an exemption grated by the TGA under section 19A of the Therapeutic Goods Act (1989) until 30 September 2018.
HEPARINISED SALINE 50IU/5ml ampoule
19 June 2018
LINK advises that due to a shortage of the Australian registered HEPARINISED SALINE 50IU/5mL (porcine mucous) 50IU/5mL injection ampoule (AUST R 66684). INK can supply Heparin Sodium 10 I.U./mL flushing solution for maintenance of patency of intravenous devices (50 I.U. in 5mL) registered and marketed in the United Kingdom.
AZACTAM (aztreonam) 1g Powder for injection shortage
11 May 2018
Bristol Myers Squibb Australia advises that due to a manufacturing issue at the active substance manufacturing plance there is a shortage of AZACTAM (aztreonam) 1g powder for injection. Current stock is likely to be depleted by 25 May 2018 with partial re-supply by mid-June. BMS recommends all health care providers prioritise aztreonam for patients they feel are in the greatest need with no other alternative.
HEPARIN SODIUM 5000 IU/0.2 mL ampoule shortage
20 April 2018
LINK advises that due to a shortage of the Australian registered DBL HEPARIN SODIUM (porcine mucous) 5000IU/0.2mL injection BP ampoule (AUST R 16349), LINK has arranged the supply of HeparinNatrium-5000-ratiopharm, heparin sodium 5000 IU/0.2 mL ampoules registered and marketed in Germany and supply is granted under an exemption granted by the Therapeutic Goods Administration under Section 19A of the Therapeutic Goods Act, 1989 until 15 October 2018.
Phenobarbitone tablets 30mg 200 delay
17 April 2018
Arrow Pharmaceutical advises that due to manufacturing capacity constrains, deliver of Phenobarb tablets 30mg 200 is not expected until early June 2018.
DANTRIUM® powder for injection 20mg vials
8 February 2018
Pfizer advises there is a shortage in Dantrium® powder for injection 20mg vials and supply of an alternative product Dantrium® Intravenous 20mg powder for solution for injection (Norgine) has been arranged on a temporary basis.
Chlorhexidine injection risks
January 2018
The Australian and New Zealand College of Anaesthetists and the Australian Commission on Safety and Quality in Health Care have developed a safety statement in response to reported incidents of accidental injection of chlorhexidine, a surface disinfectant.
DBL™ Metronidazole Intravenous Infusion 500mg in 100mL bag
8 January 2018
Pfizer advises that batch 70094/March 2019 of DBL™ Metronidazole Intravenous Infusion 500 mg in 100 mL infusion bags are being recalled based on a customer report that a single unit from a 10 unit box had visible black particles reported as mould between the infusion bag and plastic overwrap.
Methylprednisolone acetate Suspension for Injection 40mg per mL
12 December 2017
Pfizer advises there is an interruption to supply for DEPO-NISOLONE™ Injection 40mg per mL and there will be an interruption to the supply of DEPO-MEDROL™ Injection 40mg per mL from late January 2018, due to unexpected manufacturing delay.
DBL™ Diazepam Injection 10mg/2ml ampoules
28 November 2017
Pfizer advises there is an interruption in supply for DBL™ Diazepam Injection 10 mg/2ml ampoules, due to an unexpected manufacturing delay. Judicious use of ampoules is recommended during the current constraints on supply and use should be reserved where no therapeutic alternatives are available.
Hydroxyurea
22 November 2017
Bristol Myers-Squibb advises there is a global shortage of supply of HYDREA hydroxycarbamide (hydroxyurea) and that stocks will be depleted by early December 2017. It is expected that supply will be re-instated by 15 January 2018.
Methotrexate Injection BP 50mg/2 mL vial shortage
15 November 2017
Pfizer advises there is an interruption in supply for Methotrexate Plastic Cytosafe Vial 50 mg/2mL (Pfizer) and DBL™ Methotrexate Injection BP 50 mg/2 mL vial, due to an unexpected manufacturing delay.
Pamisol 15mg/5mL vial and 90mg/10mL injection vial shortage
15 November 2017
Pfizer advises there is an interruption in supply for Pamisol (disodium pamidronate) 15mg/5mL and 90mg/10mL injection vials, due to unexpected manufacturing delay.
Methotrexate Injection BP 50mg/2 mL vial shortage
26 October 2017
Pfizer advises there is an interruption in supply for Methotrexate Plastic Cytosafe Vial 50 mg/2mL (Pfizer) and DBL™ Methotrexate Injection BP 50 mg/2 mL vial, due to an unexpected manufacturing delay.
Cytarabine Injection 2g in 20 mL vial and Vincristine Sulfate Injection 2mg in 2mL vial shortage
23 October 2017
Pfizer advises there is an interruption in supply for Cytarabine Injection 2g in 20 mL vial and Vincristine Sulfate Injection 2mg in 2mL vial, due to an unexpected manufacturing delay.
Gentamicin Injection BP 80 mg in 2 mL Steriluer® - Product recall
6 October 2017
Pfizer advises that, following an internal investigation, ten batches of Gentamicin Injection BP 80 mg in 2 mL Steriluer® are being recalled as they may contain a higher than expected intrinsic constituent (histamine) in the finished product. View recall notice.
Dexamethasone sodium phosphate shortage
1 May 2017
TGA updated medicine shortage information.
Phenoxybenzamine hydrochloride shortage
1 May 2017
TGA updated medicine shortage information.
DANTRIUM (dantrolene sodium) Powder for Injection 20 mg- Updates on shortage
7 April 2017
Pfizer advises there is an interruption in supply for Dantrium (dantrolene sodium) powder for injection 20mg, due to an unexpected manufacturing delay.
Previous notice.
EpiPen 300 microgram adrenaline injection syringe auto-injector
20 March 2017
The TGA has issued recall for four batches of the EpiPen 300 microgram adrenaline injection syringe auto-injector. EpiPens from affected batches can be returned to pharmacies for a refund or exchanged for one from a different, unaffected batch free of charge.
Etopophos (etoposide phosphate) powder for injection vials and Vepesid etoposide capsules
14 February 2017
The TGA have announced that there are current shortages of Etopophos etoposide 1 g (as phosphate) and Etopophos etoposide phosphate 113.6 mg (equivalent to 100 mg etoposide) powder for injection vials and Vepesid etoposide 50 mg capsule blister packs. The Vepesid etoposide 100 mg capsule blister pack shortage has been resolved.
Glyceryl trinitrate tablets (Anginine and Lycinate) potential medicine shortage and alternative product
9 February 2017
The TGA have announced that following the potential shortage of glyceryl trinitrate tablets due to reformulation, an alternative supply (Nitrostat tablets) has now been approved. Please note that the TGA anticipate a shortage for the alternative product 600 mcg (0.6 mg) of Nitrostat tablets.
Metformin tablet shortage — Updates on availability
19 January 2017
The TGA has released a statement advising consumers and health professionals about a change in status in the availability of metformin extended release tablets.
Stonefish Antivenom 2000U Injection Vial
10 January 2017
Seqirus advises that Stonefish AV Lot 056007501 has 2.52 mL product volume, instead of the volume of 2.29 mL.
Urgent recall for Dilantin
5 December 2016
Pfizer issued a recall of dilantin (phenytoin sodium) 30 mg capsule bottle, 100 mg capsule bottle and dilantin (phenytoin) infatabs 50 mg tablet bottle.
Discontinuation of Modecate (fluphenazine decanoate) injection
1 December 2016
Bristol Myers Squibb advise that they will cease supply of Modecate (fluphenazine decanoate) injection and expect supply to be depleted between March and August 2017. The information is also available via the TGA website.
Supply information regarding Etopophos inj (etoposide phosphate),Vumon inj (teniposide) and Vepesid (etoposide)
25 November 2016
Bristol Myers Squibb have released updates in the supply of three medicines. Etopophos inj (etoposide phosphate) remains out of stock. Vumon inj (teniposide) is to cease supply due to the end of global production and Vepesid (etoposide) 50mg capsules are in short supply, with the next shipment expected to arrive mid-December 2016. Update: Vepesid (etoposide) 50mg capsules are still in short supply.
Aciclovir 250 mg/10 mL injection anticipated shortage
11 November 2016
Medicine shortage information about aciclovir injection has been posted on the TGA website.
Carbimazole Manufacturing Delays
6 October 2016
Link Healthcare has issued a notification to address the shortage of Australian registered carbimazole 5mg tablets. Link has been granted TGA approval to supply German registered Carbimzol Aristo 5mg tablets.
Angiomax (bivalirudin) updated safety information
1 October 2016
The Medicines Company issued a letter to inform of updates in important new safety information regarding contraindications, precautions, dosage and administration of angiomax (bivalirudin).
Recall for GlucaGen HypoKit
12 September 2016
The TGA has released a statement regarding their decision to recall four batches of the GlucaGen HypoKit. It has been identified that a small number of GlucaGen HypoKits have needles which may become detached from the pre-filled syringes. Patients who return affected products will be given free replacements.
Recall for APO-Cabergoline
2 September 2016
The TGA has released a statement regarding Apotex and their decision to recall one batch of APO-Cabergoline 500mcg tablets due to a packaging issue, which could potentially lead to the product degrading over time in moist conditions.
Safety alert for Actilyse (alteplase)
22 August 2016
Boehringer Ingelheim has issued a safety alert regarding an issue during reconstitution of Actilyse (alteplase (rch)) 50 mg powder for injection. Boehringer Ingelheim emphasises the importance of strict compliance with handling instructions provided on the packaging of the transfer cannula.
Monoplus and Monopril discontinuation
22 August 2016
Bristol-Myers Squibb has issued a letter regarding the decision to discontinue Monoplus 10mg (fosinopril 10mg and hydrochlorothiazide 12.5mg), Monoplus 20mg (fosinopril 20mg and hydrochlorothiazide 12.5mg) and Monopril 20mg (fosinopril 20mg) tablets in Australia.
